Dr Virginia Acha, Executive Director - Research, Medical and Innovation, said:
“Animal research continues to plays a vital role in bio-medical research, helping us to better understand and improve the treatment of debilitating and life threatening disease in both humans and animals. This research has contributed to the introduction of safe and effective medicines for diseases including cancer, diabetes, and HIV, saving millions of lives worldwide. There are currently no in-vitro or computer models which can currently eradicate the need for all animal testing in the development of new medicines.
It is important to note that the numbers of animals used was calculated differently in 2014, in line with new EU legislation which aims to regulate and improve standards across Europe. Therefore it is not possible to accurately compare the figures with previous years.
We fully support the publication of actual severity information for the first time as we believe that this further increases transparency and will help facilitate open and informed debate on the use of animals in bio-medical research.
By law the use of animals in research must be in line with the 3Rs which aims to replace animals with non-animal techniques or less sentient species, reduce numbers used and refine procedures as much as possible in order to reduce harm. The ABPI and our members remain committed to the 3Rs, and our collaboration with the National Centre for the Replacement, Refinement and Reduction of Animals in Research is now in its 11th year."
Notes to editors
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Media Team
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 7147